Brief: Newamsterdam Pharma Highlights 2025 Achievements And Outlines 2026 Strategic Priorities
09/01/2026 13:36
Jan 9 (Reuters) - NewAmsterdam Pharma Company NV KH6.F: NEWAMSTERDAM PHARMA HIGHLIGHTS 2025 ACHIEVEMENTS AND OUTLINES 2026 STRATEGIC PRIORITIES NEWAMSTERDAM PHARMA COMPANY NV - EMA APPROVAL DECISION FOR OBICETRAPIB EXPECTED IN H2 2026 NEWAMSTERDAM PHARMA COMPANY NV - RUBENS PHASE 3 TRIAL EXPECTED TO ENROLL APPROXIMATELY 300 PATIENTS, WITH TOPLINE DATA EXPECTED BY YEAR END 2026 Source text: ID:nGNX5PcsMG Further company coverage: KH6.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on NewAmsterdam Pharma
See all newsBrief: Menarini Group & Newamsterdam Pharma Receive European Commission Approval For Ubeslo And Evlarco
Amgen falls after Novartis trial setback, BMO downgrade
Brief: Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion For Obicetrapib And Obicetrapib/Ezetimibe
Brief: NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)